title: Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
abstract: Oxaliplatin is a highly neurotoxic chemotherapeutic agent routinely used for the treatment of colorectal cancer. Recent data suggest that oxaliplatin-induced peripheral neuropathy may be long-lasting; however, the effects of persistent neuropathy on colorectal cancer survivors' physical and emotional well-being are not well understood. This cross sectional, descriptive study included persons who had received oxaliplatin-based chemotherapy for treatment of colorectal cancer at Moffitt Cancer Center between 2003 and 2010. Questionnaires including the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, Center for Epidemiological Studies Depression Scale (CES-D), Insomnia Severity Index, Medical Outcomes Study Short Form 36, and a demographic survey were administered. Pearson's correlations and linear regression analyses were used to examine relationships between neuropathy and depressive symptoms, sleep quality, and health-related quality of life (HRQOL). Eighty-nine percent of participants reported at least one symptom of peripheral neuropathy with a mean of 3.8 (±2.4) neuropathic symptoms. Depressive symptoms on the CES-D were significantly associated with more severe peripheral neuropathy(r = 0.38, p = 0.0001) and interference with activities (r = 0.59, p < 0.0001). Higher degrees of sleep disturbance on the Insomnia Severity Index (ISI) were significantly associated with more severe peripheral neuropathy (r = 0.35, p = 0.0004) and interference with activities(r = 0.52, p < 0.0001). HRQOL was significantly associated with peripheral neuropathy and interference with activities.
authors.affiliation: College of Nursing, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 22, Tampa, FL, 33612-4766, USA, ctofthag@health.usf.edu.
authors.forename: Cindy
authors.initials: C
authors.lastname: Tofthagen
authors.forename: Kristine A
authors.initials: KA
authors.lastname: Donovan
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Morgan
authors.forename: David
authors.initials: D
authors.lastname: Shibata
authors.forename: Yating
authors.initials: Y
authors.lastname: Yeh
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000503:physiopathology / Q000523:psychology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D017063:Outcome Assessment, Health Care; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D011788:Quality of Life; D011795:Surveys and Questionnaires; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin
references.citation: Clin Cancer Res. 2006 May 15;12(10):3050-6
references.pmid: 16707601
references.citation: Anticancer Drugs. 2006 Jan;17(1):103-5
references.pmid: 16317297
references.citation: Ann Oncol. 2012 Dec;23(12):3116-3122
references.pmid: 22865779
references.citation: Eur J Cancer. 2005 May;41(8):1135-9
references.pmid: 15911236
references.citation: J Support Oncol. 2006 Sep;4(8):398-9
references.pmid: 17004514
references.citation: Lancet Oncol. 2011 Jul;12(7):642-53
references.pmid: 21641867
references.citation: Am J Clin Oncol. 2013 Aug;36(4):331-7
references.pmid: 22547012
references.citation: Ann Oncol. 2013 Feb;24(2):454-462
references.pmid: 22910842
references.citation: J Pain Symptom Manage. 2008 Jan;35(1):31-9
references.pmid: 17980550
references.citation: Cancer Nurs. 2011 Jul-Aug;34(4):E10-20
references.pmid: 21242773
references.citation: J Palliat Med. 2010 Nov;13(11):1389-91
references.pmid: 21091028
references.citation: Med Care. 1992 Jun;30(6):473-83
references.pmid: 1593914
references.citation: Oncol Nurs Forum. 2004 May;31(3):615-23
references.pmid: 15146227
references.citation: J Pain. 2006 Dec;7(12):892-900
references.pmid: 17157775
references.citation: Lancet Oncol. 2011 Nov;12(12):1151-61
references.pmid: 21719347
references.citation: J Pain Symptom Manage. 2005 Oct;30(4):374-85
references.pmid: 16256902
references.citation: Psychooncology. 2005 Jun;14(6):429-41
references.pmid: 15376284
references.citation: Oncologist. 2011;16(5):708-16
references.pmid: 21478275
references.citation: Muscle Nerve. 2005 Jul;32(1):51-60
references.pmid: 15880395
references.citation: Nurs Res. 2007 Sep-Oct;56(5):323-31
references.pmid: 17846553
references.citation: Cancer. 2013 Jan 15;119(2):438-44
references.pmid: 22786764
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1247-54
references.pmid: 17401013
references.citation: Clin J Pain. 2006 Oct;22(8):681-5
references.pmid: 16988563
references.citation: Clin J Oncol Nurs. 2010 Jun;14(3):E22-8
references.pmid: 20529785
references.citation: Psychol Aging. 1997 Jun;12(2):277-87
references.pmid: 9189988
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6359-68
references.pmid: 17975148
references.citation: Cancer Nurs. 1988 Feb;11(1):23-32
references.pmid: 2834044
references.citation: Eur Neurol. 2006;56(1):13-6
references.pmid: 16825773
references.citation: Support Care Cancer. 2006 Mar;14(3):223-9
references.pmid: 16021477
references.citation: AIDS Res Treat. 2012;2012:961510
references.pmid: 22570772